Siemens Healthineers and Novo Partner on Liver Tests

The companies have launched a joint effort to improve diagnostic access and awareness for liver fibrosis.

Updated on Sept. 21, 2026 in Diabetes

Bold vector editorial illustration of a row of clear glass medical vials, representing blood-based diagnostic testing for liver health. — Siemens Healthineers and Novo have partnered to improve access to blood-based liver fibrosis testing, aiming to streamline diagnosis for patients across the United States. AI Illustration. Upload story photo >

Live Poll

Do you believe medical companies should prioritize blood tests over traditional biopsy for early diagnosis?

Siemens Healthineers and Novo have teamed up to advance the use of blood tests for liver fibrosis in the United States. This collaboration seeks to improve patient outcomes for those suffering from metabolic dysfunction-associated steatotic liver disease.

Why it matters

The partnership aims to replace invasive biopsy or imaging methods with more accessible blood tests to help identify patients eligible for treatment. By streamlining diagnostic pathways, the companies hope to increase early intervention rates for liver disease.

Nearly 25 percent of U.S. adults are affected by MASLD. The Enhanced Liver Fibrosis test, which runs on Atellica immunoassay machines, was granted FDA de novo clearance in 2021.

The players

Siemens Healthineers

This is a global medical technology company that provides laboratory diagnostics and imaging equipment.

Novo

This is a pharmaceutical company that specializes in treatments for diabetes and obesity, formerly known as Novo Nordisk.

The details

The collaboration leverages the Enhanced Liver Fibrosis test to track MASH progression and support clinical care decisions. By focusing on blood-based diagnostics, the companies aim to remove barriers to therapy that traditionally rely on imaging or biopsy.

Siemens Healthineers received FDA clearance for the Enhanced Liver Fibrosis test in 2021.
Novo received FDA accelerated approval for Wegovy for MASH in August 2025.
Novo officially dropped Nordisk from its name in September 2026.

Cancer
Sept. 21
SAFE Score Outperformed Other Liver Disease Risk Metrics
Artificial Intelligence
Sept. 21
FDA Cleared New AI Tool for CT Scan Triage
Weight Loss
Sept. 21
RNA Therapy Enhanced Fat Loss in Mice Study

The Big Picture

This collaboration follows the FDA's de novo classification pathway for the Enhanced Liver Fibrosis test, which set the regulatory precedent for current diagnostic standards. It marks a broader shift in integrating pharmaceutical therapy with non-invasive diagnostic biomarkers.

Patients may find it easier to monitor their liver health through non-invasive blood tests instead of undergoing traditional biopsies. This shift could simplify the care process for those requiring MASH treatment and potentially increase the number of patients who qualify for therapy.

The takeaway

Patients should consult with their healthcare providers about whether blood-based liver assessments are appropriate for their specific diagnostic needs. This partnership emphasizes the growing reliance on non-invasive screening tools to manage chronic liver conditions effectively.